Learn about Merck’s research into immuno-oncology medicines that harness the patient’s immune system to fight cancer, including targeting programmed death-ligand 1 (PD-L1)
Learn about Merck’s research into immuno-oncology medicines that harness the patient’s immune system to fight cancer, including targeting T-cell immunoglobulin and ITIM domain (TIGIT)
Log in to the STARTone Portal for information on investigator-sponsored studies and grants to support Independent Medical Education (IME) and Continuing Medical Education (CME), Fellowships and Treatment Guidelines
5 Min
Welcome to Merck Healthcare!
Help us direct you to the right information by selecting one of the following options: